BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of BMS-214662 plus trastuzumab in treating patients
who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor
cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab
can locate tumor cells and either kill them or deliver tumor-killing substances to them
without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may
kill more tumor cells